Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed b...

Full description

Saved in:
Bibliographic Details
Main Authors: Januario E. Castro, Paula A. Lengerke-Diaz, Juliana Velez Lujan, Michael Y. Choi, Eider F. Moreno-Cortes, Jose V. Forero, Juan Esteban Garcia-Robledo, Chaja Jacobs, Colin McCarthy, Alaina Heinen, Carlos I. Amaya-Chanaga, Thomas J. Kipps
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2022/4450824
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1155/2022/4450824

Similar Items